HDAC3 and cholangiocarcinoma: Down-regulation or pharmacological inhibition of HDAC3 by novel class I inhibitors, such as 4SC202, BG45, or SBHA, can inhibit cholangiocarcinoma (CCA) growth and promote apoptosis [17].